View Past PerformanceBeroni Group バランスシートの健全性財務の健全性 基準チェック /26Beroni Groupの総株主資本はA$5.6M 、総負債はA$976.0Kで、負債比率は17.3%となります。総資産と総負債はそれぞれA$8.9MとA$3.2Mです。主要情報17.29%負債資本比率AU$976.00k負債インタレスト・カバレッジ・レシオn/a現金AU$894.01kエクイティAU$5.65m負債合計AU$3.23m総資産AU$8.87m財務の健全性に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 01Beroni Group Limited, Annual General Meeting, May 29, 2026Beroni Group Limited, Annual General Meeting, May 29, 2026. Location: at level 16, 175 pitt street, sydney nsw 2000 australia Australiaお知らせ • Aug 30Beroni Group Limited, Annual General Meeting, Oct 01, 2024Beroni Group Limited, Annual General Meeting, Oct 01, 2024. Location: level 16, 175 pitt street, 2000 australia, sydney nsw Australiaお知らせ • Jun 02Beroni Group Limited Announces That It Has Received Notification from Its European Authorized RepresentativeBeroni Group Limited announced that it has received notification from its European Authorized Representative, CMC Medical Devices & Drugs SL, that its latest enhanced COVID-19 Antigen Rapid Test Kit - Colloidal Gold Method (“Rapid Test Kit”) has complied with the applicable essential requirements of the council directive 98/79/EEC in vitro diagnostics as amended. Since its launch in 2020, the Rapid Test Kit has been further optimized and upgraded with greatly improved performance indicators. The enhanced Rapid Test Kit is not only simple and convenient to use but also is further improved with faster detection time and higher level of accuracy.お知らせ • Apr 01Beroni Group Limited Appoints John Chiplin to the Board of DirectorsBeroni Group Limited announced that it has appointed Dr. John Chiplin as an independent director to Beroni’s Board of Directors effective April 1, 2022. Dr. Chiplin is an accomplished biotech executive and investor with a proven track record of building successful biotech companies. Dr. John Chiplin, PhD is Managing Director of Newstar Ventures Ltd. and Chairman of the Board of Biotherapy Services, N4 Pharma plc and Scancell Holdings plc. Dr. Chiplin has significant operational, investment and international experience in the life science and technology industries. From 2014 to 2016, he served as executive director of Benitec Biopharma Inc. and helped executed the company’s US IPO.お知らせ • Sep 10Beroni Group Receives Approval for 43.5% R&D Rebate from Australian Government for the Novel, Potential Anti-Cancer Drug PENAOBeroni Group announced that PENAO Pty Ltd, its majority-owned, Sydney-based anti-cancer drug development company, has been approved by the Australian government for the annual 43.5% R&D rebate of eligible expenditure. The approval also includes R&D overseas activities so long as the total overseas expenditure claim over the life of the R&D activities is less than the expected total expenditure on the Australian R&D activities to which they are scientifically linked. The PENAO drug manufacture is expected to complete in the first half of 2022. Raw materials have been procured, familiarization studies have been completed and optimization work is progressing well at Aurigene Pharmaceutical Services Ltd, India.お知らせ • Sep 02Beroni Group Announces the Latest Clinical Study of its SARS-CoV-2 Antigen Test KitBeroni Group Limited announced the latest clinical study of its SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) demonstrated an overall sensitivity of 95% and specificity of 100%. The clinical study was conducted with 70 subjects providing 105 true-positive specimens and 105 true-negative specimens. The results for the different types of swab sampling are as follows: Nasal sampling - sensitivity 92%; specificity 100%; Nasopharyngeal sampling - sensitivity 97%; specificity 100%; Oropharyngeal sampling - sensitivity 95%; specificity 100%. Beroni Group’s SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) received CE certification in December 2020 and was granted authorization for export in April 2021. The product can be used for in vitro qualitative auxiliary detection of SARS-CoV-2 antigen specimens and is for professional use only.お知らせ • May 29Beroni Group Limited announced that it has received $2 million in fundingBeroni Group Limited (NSX:BTG) announced a private placement of 20,000 convertible notes at a price of $100 per note for gross proceeds of $2,000,000 on May 28, 2021. The transaction included participation from an investor in Japan. The notes are zero coupon notes with a maturity date of May 27, 2022 and are convertible into common shares at a conversion price of $10. The number of shares to be issued in respect of each convertible note will be calculated by dividing the face value of the notes by the conversion price. Some or all of the convertible notes can be converted at the election of the noteholder at any time prior to maturity. The notes are issued at par.お知らせ • Apr 29Beroni Group’s SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) Has Received Export PermitBeroni Group Limited announced that it has received the notification that its SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) is granted authorization for export. This test kit requires no blood, and only a nasopharyngeal swab is needed to collect samples. It can also deliver the test results within 10 minutes. Based on clinical tests, the sensitivity, specificity and total coincidence rate of anterior nasal sampling are 95.90%, 99.19% and 97.55% respectively, while the sensitivity, specificity and total coincidence rate of nasopharyngeal and oropharyngeal sampling are 98.36%, 99.19% and 98.78% respectively.財務状況分析短期負債: BNIG.Fの 短期資産 ( A$2.3M ) は 短期負債 ( A$2.6M ) をカバーしていません。長期負債: BNIG.Fの短期資産 ( A$2.3M ) が 長期負債 ( A$601.6K ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: BNIG.Fの 純負債対資本比率 ( 1.5% ) は 満足できる 水準であると考えられます。負債の削減: BNIG.Fの負債対資本比率は、過去 5 年間で2.2%から17.3%に増加しました。貸借対照表キャッシュ・ランウェイ分析過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。安定したキャッシュランウェイ: BNIG.Fは、現在の フリーキャッシュフロー に基づくと、キャッシュランウェイ が 1 年未満です。キャッシュランウェイの予測: フリーキャッシュフローが毎年0.2 % の歴史的率で成長し続ける場合、 BNIG.Fのキャッシュランウェイは 1 年未満になります。健全な企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/10/14 15:50終値2025/07/17 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Beroni Group Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 01Beroni Group Limited, Annual General Meeting, May 29, 2026Beroni Group Limited, Annual General Meeting, May 29, 2026. Location: at level 16, 175 pitt street, sydney nsw 2000 australia Australia
お知らせ • Aug 30Beroni Group Limited, Annual General Meeting, Oct 01, 2024Beroni Group Limited, Annual General Meeting, Oct 01, 2024. Location: level 16, 175 pitt street, 2000 australia, sydney nsw Australia
お知らせ • Jun 02Beroni Group Limited Announces That It Has Received Notification from Its European Authorized RepresentativeBeroni Group Limited announced that it has received notification from its European Authorized Representative, CMC Medical Devices & Drugs SL, that its latest enhanced COVID-19 Antigen Rapid Test Kit - Colloidal Gold Method (“Rapid Test Kit”) has complied with the applicable essential requirements of the council directive 98/79/EEC in vitro diagnostics as amended. Since its launch in 2020, the Rapid Test Kit has been further optimized and upgraded with greatly improved performance indicators. The enhanced Rapid Test Kit is not only simple and convenient to use but also is further improved with faster detection time and higher level of accuracy.
お知らせ • Apr 01Beroni Group Limited Appoints John Chiplin to the Board of DirectorsBeroni Group Limited announced that it has appointed Dr. John Chiplin as an independent director to Beroni’s Board of Directors effective April 1, 2022. Dr. Chiplin is an accomplished biotech executive and investor with a proven track record of building successful biotech companies. Dr. John Chiplin, PhD is Managing Director of Newstar Ventures Ltd. and Chairman of the Board of Biotherapy Services, N4 Pharma plc and Scancell Holdings plc. Dr. Chiplin has significant operational, investment and international experience in the life science and technology industries. From 2014 to 2016, he served as executive director of Benitec Biopharma Inc. and helped executed the company’s US IPO.
お知らせ • Sep 10Beroni Group Receives Approval for 43.5% R&D Rebate from Australian Government for the Novel, Potential Anti-Cancer Drug PENAOBeroni Group announced that PENAO Pty Ltd, its majority-owned, Sydney-based anti-cancer drug development company, has been approved by the Australian government for the annual 43.5% R&D rebate of eligible expenditure. The approval also includes R&D overseas activities so long as the total overseas expenditure claim over the life of the R&D activities is less than the expected total expenditure on the Australian R&D activities to which they are scientifically linked. The PENAO drug manufacture is expected to complete in the first half of 2022. Raw materials have been procured, familiarization studies have been completed and optimization work is progressing well at Aurigene Pharmaceutical Services Ltd, India.
お知らせ • Sep 02Beroni Group Announces the Latest Clinical Study of its SARS-CoV-2 Antigen Test KitBeroni Group Limited announced the latest clinical study of its SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) demonstrated an overall sensitivity of 95% and specificity of 100%. The clinical study was conducted with 70 subjects providing 105 true-positive specimens and 105 true-negative specimens. The results for the different types of swab sampling are as follows: Nasal sampling - sensitivity 92%; specificity 100%; Nasopharyngeal sampling - sensitivity 97%; specificity 100%; Oropharyngeal sampling - sensitivity 95%; specificity 100%. Beroni Group’s SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) received CE certification in December 2020 and was granted authorization for export in April 2021. The product can be used for in vitro qualitative auxiliary detection of SARS-CoV-2 antigen specimens and is for professional use only.
お知らせ • May 29Beroni Group Limited announced that it has received $2 million in fundingBeroni Group Limited (NSX:BTG) announced a private placement of 20,000 convertible notes at a price of $100 per note for gross proceeds of $2,000,000 on May 28, 2021. The transaction included participation from an investor in Japan. The notes are zero coupon notes with a maturity date of May 27, 2022 and are convertible into common shares at a conversion price of $10. The number of shares to be issued in respect of each convertible note will be calculated by dividing the face value of the notes by the conversion price. Some or all of the convertible notes can be converted at the election of the noteholder at any time prior to maturity. The notes are issued at par.
お知らせ • Apr 29Beroni Group’s SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) Has Received Export PermitBeroni Group Limited announced that it has received the notification that its SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) is granted authorization for export. This test kit requires no blood, and only a nasopharyngeal swab is needed to collect samples. It can also deliver the test results within 10 minutes. Based on clinical tests, the sensitivity, specificity and total coincidence rate of anterior nasal sampling are 95.90%, 99.19% and 97.55% respectively, while the sensitivity, specificity and total coincidence rate of nasopharyngeal and oropharyngeal sampling are 98.36%, 99.19% and 98.78% respectively.